Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Mantarray revolutionizes the early phases of preclinical drug testing by integrating functional data with advanced technologies. By enabling simultaneous analysis of 3D engineered muscle tissues that exhibit adult-like functional characteristics, Mantarray facilitates the identification, safety assessment, and effectiveness evaluation of new therapeutics. With an impressive tissue formation success rate exceeding 95%, the Mantarray Plate Kit ensures consistent and reproducible engineered tissues across 24 wells. This innovative platform offers a user-friendly, scalable, and adaptable solution that empowers researchers to analyze 3D tissues in vitro right within their labs. Early adopters can take advantage of this groundbreaking instrument. The Mantarray system employs a unique magnetic sensing method that accurately detects the contractions of engineered muscle tissues (EMTs), allowing users to assess the contractility of 24 tissues simultaneously and in real time, greatly enhancing throughput. Moreover, the accompanying software simplifies the process by eliminating the need for manual contractility calculations, thus streamlining the research workflow. Overall, Mantarray not only improves the efficiency of drug discovery but also enhances the reliability of data obtained during preclinical studies.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
No
In Person
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
Curi Bio
Founded
2015
Country
United States
Website
www.curibio.com/mantarray
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/